Savior Lifetec Corp banner

Intrinsic Value

The intrinsic value of Savior Lifetec Corp (4167) under the Base Case is 8.28 TWD per share. Compared with the current market price of 15.75 TWD, the stock appears Overvalued by 47% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

Intrinsic Value
NT$8.28
Overvaluation 47%
Intrinsic Value
Price NT$15.75

Savior Lifetec Corp is cheaper than usual. Still overvalued, but less so than on 97% of days in the past 5 years.

Alert me when Savior Lifetec Corp is below its intrinsic value
Today NT$6.62 · 58.0% below the current price
Alternatives to Savior Lifetec Corp

Fundamental Analysis

What Savior Lifetec Does

Pharmaceuticals Health Care

Savior Lifetec Corp. engages in the development, production, and sale of active pharmaceutical ingredients and finished dosage formulations. The company is headquartered in Tainan, Tainan. The company went IPO on 2012-12-21. The Company’s main products are broad-acting antibiotics meropenem and ertapenem, which are used to fight severe clinical infections. The firm also provides API intermediates and biopharmaceutical technology services. The firm distributes its products to America, Asia, Europe and other markets.

Headquarters
Taiwan TW
Employees
384
IPO date
Dec 21, 2012
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue Research

Decided on Savior Lifetec? Get an email when Savior Lifetec Corp reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one Savior Lifetec Corp stock?

The intrinsic value for Savior Lifetec Corp (4167) under the Base Case is 8.28 TWD.

Is Savior Lifetec Corp stock undervalued or overvalued?

Compared with the current market price of 15.75 TWD, the stock appears Overvalued by 47% .

How reliable are our estimates? See how past valuations played out
Back to Top